Sanders Corners FDA Nominee Over Trump’s Drug Price Claims

Throughout the exchange, Sanders pushed for a direct answer regarding the president’s public boasts, which Overton repeatedly sidestepped. Instead of addressing the accuracy of the claim, the nominee pointed to a 3% decrease in drug prices reflected in the Consumer Price Index, attributing the shift to recent industry agreements. Sanders countered that any progress in price stabilization likely stems from the 2022 Inflation Reduction Act, which empowered Medicare to negotiate costs, rather than the policies championed by the current administration.

The tension underscored a stark divide between official rhetoric and market reality. While the White House maintains that its strategies have revolutionized affordability, independent research consistently contradicts these statements. A 2024 RAND Corporation study found that American consumers still pay nearly three times more for medications than their international counterparts. Furthermore, records from Sanders’ office indicate that drug companies increased prices on hundreds of medications during the first year of the current term, casting doubt on the administration’s narrative of record-low costs.